Leerink Partnrs Issues Positive Outlook for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for CRISPR Therapeutics in a research report issued to clients and investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.25) per share for the quarter, up from their previous estimate of ($1.33). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.34) EPS and FY2026 earnings at ($5.09) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Several other brokerages also recently commented on CRSP. Royal Bank of Canada reduced their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Stock Down 4.4 %

Shares of NASDAQ CRSP opened at $44.51 on Wednesday. The business’s 50 day moving average price is $42.29 and its two-hundred day moving average price is $46.00. The company has a market cap of $3.82 billion, a PE ratio of -10.19 and a beta of 1.67. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $90.62.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently bought and sold shares of CRSP. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $36,000. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $71,000. Sunbelt Securities Inc. boosted its holdings in shares of CRISPR Therapeutics by 108.6% in the 4th quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after purchasing an additional 3,210 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of CRISPR Therapeutics by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock valued at $27,166,000 after purchasing an additional 13,865 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in shares of CRISPR Therapeutics by 1.6% during the 4th quarter. Woodline Partners LP now owns 101,600 shares of the company’s stock worth $3,999,000 after buying an additional 1,600 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.